# The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

> **NCT03192618** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 290 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** adjuvant transarterial chemoinfusion (TAI)
- **DRUG:** mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)

## Key facts

- **NCT ID:** NCT03192618
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 290 (ESTIMATED)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03192618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03192618, "The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03192618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*